{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-25-000032","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2025-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.549832+00:00","generated_at":"2026-05-17T09:28:57.148308+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NovoCure terminates LUNAR-4 phase 2 trial for metastatic NSCLC, cites real-world evidence alternative","bullets":["Novocure GmbH terminated the LUNAR-4 phase 2 trial of Tumor Treating Fields with pembrolizumab for metastatic non-small cell lung cancer.","Decision based on availability of real-world evidence to achieve trial objectives without an interventional clinical study.","Termination is not related to any safety concerns; no impact on other Novocure studies.","Trial targeted patients previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-25-000032","json":"https://secwatch.observer/filing/0001645113-25-000032.json","markdown":"https://secwatch.observer/filing/0001645113-25-000032.md","text":"https://secwatch.observer/filing/0001645113-25-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000032/0001645113-25-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000032/nvcr-20250828.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T09:28:57.148308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}